PFE Earnings: Pfizer Tops Q1 Profit Estimates Despite Lower Sales
Pfizer (PFE) delivered stronger-than-expected earnings for Q1 2025, posting an adjusted diluted EPS of $0.92, significantly above analysts' expectations of $0.60. The earnings beat was driven by effective cost-cutting measures and solid sales of its heart medication, Vyndaqel. However, the company missed revenue expectations due to declining COVID-related sales. Pfizer reported first-quarter revenue of $13.70 billion, falling short of the projected $13.97 billion. This also marked a year-over-year decline of 8%. PFE stock gained 0.69% in pre-market trading.
Protect Your Portfolio Against Market Uncertainty
Pfizer Sticks to 2025 Forecast, but Tariff Threat Looms
Pfizer left its full-year 2025 guidance unchanged, expecting revenue between $61 billion and $64 billion. However, the company noted that this forecast does not account for any future impacts from tariffs or shifts in trade policy, which remain unpredictable. Pfizer, along with other drugmakers, faces potential challenges from proposed U.S. tariffs on pharmaceutical imports from countries like China, which is a key supplier of raw materials and medical products.
Additionally, the company expects a $1 billion decline in 2025 sales due to changes in the Medicare program under the Inflation Reduction Act, which could slow overall growth by approximately 1.6% compared to 2024.
Despite this expected headwind, the company remains focused on strengthening its financials. By the end of 2025, Pfizer aims to improve its operating margin through a cost-cutting initiative targeting roughly $4.5 billion in savings.
Is Pfizer Stock a Good Buy Right Now?
According to TipRanks, Wall Street has a Moderate Buy consensus rating on PFE stock, based on 12 Holds and six Buys assigned in the last three months. The average Pfizer stock price target of $27.75 implies over 20% upside potential.
See more PFE analyst ratings
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets in April. With the massive tariffs imposed by the United States and China currently on a pause, the markets recovered slightly. However, this is only a temporary suspension. The uncertainty around tariffs and trade production measures remains, which has muted economic growth. However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by positive pipeline and regulatory developments. Innovation is at its peak with key spaces like rare diseases, next-generation oncology treatments, obesity, immunology and neuroscience attracting investor attention. M&A activity also remains healthy. Regular pipeline setbacks, slow ramp-up of newer drugs, patent cliffs, regulatory risks and broader market concerns related to the economy are some of the headwinds for the sector. Nonetheless, large drugmakers have several robust revenue streams and are mostly profitable companies, making them safe havens for investments. Among the large drugmakers, AbbVie ABBV, Novartis NVS, Pfizer PFE, Sanofi SNY and Bayer BAYRY are worth retaining in one's portfolio. Industry Description The Zacks Large Cap Pharmaceuticals industry comprises some of the largest global companies that develop multi-million-dollar drugs for a broad range of therapeutic areas, like neuroscience, cardiovascular and metabolism, rare diseases, immunology and oncology. Some of these companies also make vaccines, animal health products, medical devices and consumer-related healthcare products. They invest millions of dollars in their product pipelines and line extensions of their already-marketed drugs. Continuous innovation is a defining characteristic of pharma companies, and these large drugmakers are constantly investing in drug development and the discovery of new medicines. Regular mergers and acquisitions, and collaboration deals are other key features of large drugmakers. What's Shaping the Future of the Large-Cap Pharma Industry? Innovation and Pipeline Success: For big drugmakers, an innovative pipeline is a competitive necessity and key to top-line growth. Pharma companies are continually striving to ramp up innovation and allocate a significant portion of their revenues to R&D. Several drugmakers are embracing AI technology to accelerate the drug discovery process for delivering more effective therapies. Successful innovation and product line extensions in key therapeutic areas, along with strong clinical study results, may serve as important catalysts for these stocks. Aggressive M&A & Collaboration Activity: The sector is characterized by aggressive M&A activities. Given that it takes several years and millions of dollars to develop new therapeutics from scratch, large pharmaceutical companies, sitting on substantial cash reserves, regularly acquire innovative small and mid-cap biotech companies to expand their pipelines. Also, sloppy sales of mature drugs, dwindling in-house pipelines, government scrutiny of drug prices and the growing use of AI for drug discovery whet the M&A appetite of large drugmakers. Moreover, collaborations and partnerships with smaller companies are in full swing. Fast-growing and lucrative markets such as oncology, rare disease and cell and gene therapy are likely to remain focus areas for M&A activities. Recently, areas such as obesity and inflammatory bowel disease have been attracting buyout interest. An important M&A deal announced recently was Sanofi's offer to acquire Blueprint Medicines for approximately $9.5 billion. M&A activity is expected to remain rampant through the rest of the year. Pipeline Setbacks & Other Headwinds: The failure of key pipeline candidates in pivotal studies and regulatory and pipeline delays can be setbacks for large drug companies and significantly hurt their share prices. Other headwinds for the industry include pricing and competitive pressure, generic competition for blockbuster treatments, a slowdown in sales of some of the most high-profile older drugs, Medicare drug price negotiations and increasing FTC scrutiny of M&A deals. Macroeconomic Uncertainty: Uncertain macroeconomic conditions, including the risk of inflation, fluctuating interest rates and instability in the financial system, along with escalating geopolitical tensions in various parts of the world, have increased broader economic woes. Uncertainties around tariffs also remain a headwind. Zacks Industry Rank Indicates a Bright Outlook The Zacks Large Cap Pharmaceuticals industry is an 11-stock group within the broader Medical sector. The group's Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks. The Zacks Large Cap Pharmaceuticals industry currently carries a Zacks Industry Rank #36, which places it in the top 15% of 245 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present a few large drug stocks that are well-positioned to outperform the market based on a strong earnings outlook, let's take a look at the industry's performance and its current valuation. Industry Versus S&P 500 & Sector The industry has outpaced the Zacks Medical Sector as well as the S&P 500 year to date. Stocks in this industry have collectively risen 3.9% so far this year against the Zacks Medical Sector's decline of 1.5%. The Zacks S&P 500 composite has risen 1.7%. YTD Price Performance Industry's Current Valuation Based on the forward 12-month price-to-earnings (P/E), a commonly used multiple for valuing large pharma companies, the industry is currently trading at 15.65X compared with the S&P 500's 21.89X and the Zacks Medical Sector's 19.31X. Over the last five years, the industry has traded as high as 20.80X, as low as 12.92X and at a median of 15.65X, as the chart below shows. Forward 12-Month Price-to-Earnings (P/E) Ratio 5 Large Drugmakers to Watch Bayer: The company's key drugs, Nubeqa for cancer and Kerendia for chronic kidney disease associated with type II diabetes, are fueling growth in its Pharmaceuticals division. Bayer is also working to expand the labels of Nubeqa and Kerendia, which, if successful, can further drive growth. The company also plans to launch two new drugs in 2025, which are elinzanetant, a hormone-free treatment for menopause symptoms, and ceramides, a drug for the treatment of a certain form of heart disease. The Consumer Health segment also improved in 2024 due to the launch of new products, which should keep the momentum in 2025. However, sales in the Crop Science division declined significantly in the past couple of years due to lower volumes and prices for glyphosate-based products. This Zacks Rank #2 (Buy) company's shares have risen 61.9% so far this year. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Estimates for its 2025 earnings per share have increased from $1.19 to $1.25 over the past 60 days. Price and Consensus: BAYRY Pfizer: It is one of the largest and most successful drugmakers in the field of oncology. The company's position in oncology was strengthened with the addition of Seagen in 2023. Though COVID revenues are declining, its non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Pfizer faces its share of challenges, the key being declining sales of its COVID-19 products. It also expects a significant impact from the loss of patent exclusivity in the 2026-2030 period, as several of its key products may face patent expirations. The Medicare Part D redesign under the Inflation Reduction Act (IRA) is also expected to negatively impact sales of Pfizer's higher-priced drugs, such as Vyndaqel, Ibrance, Xtandi and Xeljanz,in 2025. However, as COVID-related uncertainties dwindle, its revenue volatility is also declining. The company's non-COVID drugs and contribution from new and newly acquired products should continue to drive top-line growth in 2025. Also, Pfizer expects cost cuts and internal restructuring to deliver savings of at least $6.0 billion. Continued growth in non-COVID sales and significant cost-reduction measures should drive profit growth. Pfizer has a Zacks Rank #2 at present. The Zacks Consensus Estimate for 2025 EPS has risen from $2.98to $3.06 per share over the past 60 days. The stock has lost 4.2% year to date. Price and Consensus: PFE Novartis: With the separation of Sandoz, Novartis has become a pure-play pharmaceutical company. Novartis maintains strong momentum on the back of a strong and diverse portfolio with drugs like Kisqali, Kesimpta, Pluvicto and Leqvio. The uptake of Pluvicto and Scemblix has been outstanding and should propel top-line growth. Approval of new drugs and label expansion of existing drugs should enable Novartis to offset the adverse impacts of the generic competition of key drugs. Novartis is also looking to solidify its presence in the promising gene therapy space. The recent spate of acquisitions and collaborations has strengthened its pipeline. However, generic erosion of some drugs and recent pipeline setbacks are a concern. Novartis has a Zacks Rank #2 at present. The Zacks Consensus Estimate for this Swiss drugmaker's 2025 EPS has risen from $8.46 to $8.74 over the past 60 days. The stock has risen 25.6% so far this year. Price and Consensus: NVS AbbVie: It has successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and should support top-line growth in the next few years. AbbVie expects to return to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE, driven by its ex-Humira platform. Boosted by its new product launches, AbbVie expects to return to robust mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as it has no significant LOE event for the rest of this decade. Strong sales performance of drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs like Ubrelvy, Elahere, Epkinly and Qulipta, should keep driving the company's top line. AbbVie has several early/mid-stage pipeline candidates with blockbuster potential. The company expects several regulatory submissions, approvals and key data readouts in the next 12 months. The company has been on an acquisition spree in the past couple of years, which is strengthening its pipeline. AbbVie has a Zacks Rank #3 (Hold) at present. The stock has risen 9.5% year to date. The Zacks Consensus Estimate for 2025 earnings has remained stable at $12.28 per share over the past 60 days. Price and Consensus: ABBV Sanofi: Dupixent has become the key top-line driver for Sanofi as it enjoys strong demand across all approved indications and geographies. New uses, increased penetration in approved indications and further geographic expansion are expected to drive Dupixent's sales in future quarters. Sanofi possesses a leading vaccine portfolio, which drives the top line. Several new drugs were launched in the past couple of years that have become significant contributors to Sanofi's accelerated top-line growth profile. Sanofi increased R&D investments and achieved significant progress with its pipeline in 2024. It has also been active on the M&A front. However, generic erosion of Aubagio in all key markets and lower sales from mature products are hurting sales. Other headwinds include the weak sales of influenza vaccines and regular negative pipeline developments. Sanofi has a Zacks Rank #3 at present. The stock has risen 6.3% year to date. The Zacks Consensus Estimate for 2025 EPS has risen from $4.43 to $4.56 over the past 60 days. Price and Consensus: SNY Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Winnipeg Free Press
8 hours ago
- Winnipeg Free Press
As GOP pushes spending cuts, many say Medicaid and food stamps are underfunded: AP-NORC poll
WASHINGTON (AP) — As Republican senators consider President Donald Trump's big bill that could slash federal spending and extend tax cuts, a new survey shows most U.S. adults don't think the government is overspending on the programs the GOP has focused on cutting, like Medicaid and food stamps. Americans broadly support increasing or maintaining existing levels of funding for popular safety net programs, including Social Security and Medicare, according to the poll from The Associated Press-NORC Center for Public Affairs Research. They're more divided on spending around the military and border security, and most think the government is spending too much on foreign aid. The poll points to a disconnect between Republicans' policy agenda and public sentiment around the domestic programs that are up for debate in the coming weeks. Here's the latest polling data on how Americans view federal funding: Most want Medicaid and SNAP funding increased or kept as is Many Americans see Medicaid and food assistance programs as underfunded — even as Congress proposes significant cuts to Medicaid and food and nutrition assistance programs — and few say 'too much' money is going to these programs. About half of U.S. adults say 'too little' funding goes to Medicaid, which is a government health care coverage program for low-income people and people with certain disabilities. Nearly half, 45%, say food and nutrition assistance programs like food stamps, SNAP or EBT cards are underfunded, according to the poll. About 3 in 10 U.S. adults in each case say those programs are receiving 'about the right amount' of funding, indicating that most Americans likely do not want to see significant cuts to the two programs. About 2 in 10 say Medicaid is overfunded, while about one-quarter say that about food assistance programs. Republicans are especially likely to say 'too much' is spent on food and nutrition assistance programs when compared with Democrats and independents — 46% of Republicans say this, compared with about 1 in 10 Democrats and independents. When it comes to Medicaid, fewer Republicans, about one-third, say the government is spending 'too much.' Many believe Medicare, Social Security and education are underfunded About 6 in 10 Americans say there is not enough government money going toward Social Security, Medicare or education broadly. But Democrats overwhelmingly think 'too little' money is allocated to these areas, while Republicans are happier with the status quo. Very few think Medicare, Social Security and education are getting 'too much' funding. Only about 1 in 10 Republicans say this about either Medicare or Social Security. Roughly one-quarter of Republicans say too much is spent on education. When it comes to Social Security, about half of Republicans say 'too little' is spent, compared with about 7 in 10 Democrats. Americans are divided on money for border security and the military Americans are more divided on whether the government is devoting too much money to the military or border security. About 3 in 10 say the government is spending 'too much' on the military, while a similar share say the government is spending 'too little.' Close to 4 in 10 say the government is spending 'about the right amount.' Republicans are much less likely to say 'too little' is being spent on border security than they were before Trump took office again in January. Now, 45% of Republicans say 'too little' is being spent, down from 79% in a January AP-NORC poll. On the other hand, Democrats are more likely to say that 'too much' is being spent on border security. About half of Democrats now say this, compared with about 3 in 10 in January. Most US adults say foreign aid gets too much funding The Trump administration has asked Congress for deep reductions to foreign aid programs, including cuts to global health programs and refugee resettlement initiatives. Foreign aid is one area with more general agreement that there is 'too much' federal spending. Most U.S. adults, 56%, say the U.S. government is spending too much on assistance to other countries, which is down from 69% in an AP-NORC poll from March 2023. There is a deep partisan divide on the issue, though. About 8 in 10 Republicans say the country is overspending on foreign aid, compared with about one-third of Democrats. ___ The AP-NORC poll of 1,158 adults was conducted June 5-9, using a sample drawn from NORC's probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for adults overall is plus or minus 4 percentage points.
Globe and Mail
3 days ago
- Globe and Mail
Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graft vs Host Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Graft vs Host Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Graft vs Host Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graft vs Host Disease Market. The Graft vs Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Graft vs Host Disease Pipeline Report: Companies across the globe are diligently working toward developing novel Graft vs Host Disease treatment therapies with a considerable amount of success over the years. Graft vs Host Disease companies working in the treatment market are Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others, are developing therapies for the Graft vs Host Disease treatment Emerging Graft vs Host Disease therapies in the different phases of clinical trials are- ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others are expected to have a significant impact on the Graft vs Host Disease market in the coming years. In April 2025, The California Institute for Regenerative Medicine (CIRM) has granted $8 million to biotech firm Tr1X to advance its Phase I/IIa clinical trial of TRX103. This therapy aims to prevent graft-versus-host disease (GvHD) in blood cancer patients receiving mismatched stem cell transplants. TRX103 is an allogeneic, engineered type 1 regulatory (Tr1) Treg cell therapy designed to reduce transplant-related complications and improve patient outcomes. In March 2025, Orca Bio's investigational T-cell immunotherapy for blood cancers significantly improved outcomes, more than doubling the rate of patients who remained free from moderate-to-severe chronic graft-versus-host disease (GvHD). According to results from the Phase III Precision-T trial (NCT05316701), 78% of patients treated with Orca-T (TRGFT-201), the company's lead allogeneic T-cell therapy, were GvHD-free after one year, compared to only 38% in the group receiving standard allogeneic stem cell transplants. In January 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech company specializing in Microbiome Ecosystem Therapies™ (MET) aimed at improving survival outcomes in cancer patients through immune system modulation, has announced positive topline results from its pivotal Phase 3 ARES trial. This single-arm, open-label, multicenter study conducted across Europe assessed the safety and efficacy of MaaT013 in patients with acute Graft-versus-Host Disease involving the gastrointestinal tract (GI-aGvHD) who are in third-line treatment — meaning they are resistant to steroids and either refractory or intolerant to ruxolitinib. The trial successfully achieved its primary endpoint, with a 28-day gastrointestinal overall response rate (GI-ORR) of 62%, significantly surpassing the expected rate of 38%. These outcomes, evaluated by an Independent Review Committee (IRC), exceeded the predefined efficacy threshold and underscore the strong clinical potential of MaaT013 in treating third-line GI-aGvHD. In December 2024, The FDA has granted approval to Mesoblast's allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L, for treating steroid-refractory acute graft versus host disease (GvHD) in pediatric patients aged two months and older. Significantly, this marks the first FDA-approved MSC-based therapy. The treatment will be commercially available under the brand name Ryoncil. Graft vs Host Disease Overview Graft versus Host Disease (GvHD) is a medical condition that can occur after a stem cell or bone marrow transplant, where the donor's immune cells (graft) recognize the recipient's body (host) as foreign and attack it. GvHD commonly affects the skin, liver, and gastrointestinal tract. It is classified into acute and chronic forms, with symptoms ranging from mild rashes and diarrhea to severe organ damage. Management typically involves immunosuppressive therapies to reduce the immune response. Emerging Graft vs Host Disease Drugs Under Different Phases of Clinical Development Include: ABSK021: Abbisko Therapeutics SYN-004: Theriva Biologics SER-155: Seres Therapeutics CB103: Cellestia Biotech Glasdegib: Pfizer TQ 05105: Chia Tai Tianqing Pharmaceutical RGI-2001: Regimmune Corporation Axatilimab: Syndax Pharmaceuticals MaaT013: MaaT Pharma MC 0518: Medac Itolizumab: Equillium Elranatamab: Pfizer Felzartamab: Janssen Pharmaceutical T-Guard: Xenikos MaaT013: MaaT Pharma Axatilimab: Syndax Pharmaceuticals TQ 05105: Chia Tai Tianqing Pharmaceutical Group Graft vs Host Disease Route of Administration Graft vs Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Intravenous Subcutaneous Graft vs Host Disease Molecule Type Graft vs Host Disease Products have been categorized under various Molecule types, such as Small molecule Cell Therapy Peptides Polymer Small molecule Gene therapy Graft vs Host Disease Pipeline Therapeutics Assessment Graft vs Host Disease Assessment by Product Type Graft vs Host Disease By Stage and Product Type Graft vs Host Disease Assessment by Route of Administration Graft vs Host Disease By Stage and Route of Administration Graft vs Host Disease Assessment by Molecule Type Graft vs Host Disease by Stage and Molecule Type DelveInsight's Graft vs Host Disease Report covers around 50+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Graft vs Host Disease product details are provided in the report. Download the Graft vs Host Disease pipeline report to learn more about the emerging Graft vs Host Disease therapies Some of the key companies in the Graft vs Host Disease Therapeutics Market include: Key companies developing therapies for Graft vs Host Disease are - Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology, AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others. Graft vs Host Disease Pipeline Analysis: The Graft vs Host Disease pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Graft vs Host Disease with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft vs Host Disease Treatment. Graft vs Host Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Graft vs Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft vs Host Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Graft vs Host Disease Pipeline Market Drivers Increase in the number of patients suffering from chronic GvHD, robust Pipeline of GvHD are some of the important factors that are fueling the Graft vs Host Disease Market. Graft vs Host Disease Pipeline Market Barriers However, high cost of treatment, recognizing the limitations of currently available aGVHD therapies and other factors are creating obstacles in the Graft vs Host Disease Market growth. Scope of Graft vs Host Disease Pipeline Drug Insight Coverage: Global Key Graft vs Host Disease Companies: Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others Key Graft vs Host Disease Therapies: ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others Graft vs Host Disease Therapeutic Assessment: Graft vs Host Disease current marketed and Graft vs Host Disease emerging therapies Graft vs Host Disease Market Dynamics: Graft vs Host Disease market drivers and Graft vs Host Disease market barriers Table of Contents 1. Graft vs Host Disease Report Introduction 2. Graft vs Host Disease Executive Summary 3. Graft vs Host Disease Overview 4. Graft vs Host Disease- Analytical Perspective In-depth Commercial Assessment 5. Graft vs Host Disease Pipeline Therapeutics 6. Graft vs Host Disease Late Stage Products (Phase II/III) 7. Graft vs Host Disease Mid Stage Products (Phase II) 8. Graft vs Host Disease Early Stage Products (Phase I) 9. Graft vs Host Disease Preclinical Stage Products 10. Graft vs Host Disease Therapeutics Assessment 11. Graft vs Host Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Graft vs Host Disease Key Companies 14. Graft vs Host Disease Key Products 15. Graft vs Host Disease Unmet Needs 16 . Graft vs Host Disease Market Drivers and Barriers 17. Graft vs Host Disease Future Perspectives and Conclusion 18. Graft vs Host Disease Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
